Replies to post #112283 on Biotech Values

[DewDiligence]

(PPHM)—Apropos to the comment in #msg-58637899 that management must think PPHM investors are the biggest suckers on the planet (from #msg-58640303):

Bavituximab will be used in all cancer regimens within 5 years! This is a direct quote from BC. I took a walk to longwood ave to visit Harvard Med last weekend and spoke with many 4th year students. Bavituximab is well known and understood here this is the future and these grads are already aware of the study going on here. Whats to come in the coming months will be ground breaking. Cotara will not be going to phase 3 [i.e. it will be FDA-approved based on phase-2] Im told that Garnick is already working with the FDA on requirements for the NDA which Peregrine plans to submit partnered or not by this time next year. Bavituximab NDA planned for 2nd quarter 2012 based on registrational phase 2b data! People are talking 6-8billion market cap by then!

I rest my case.